Follow us on Twitter
twitter icon@FreshPatents


Infectious patents

      

This page is updated frequently with new Infectious-related patent applications.

SALE: 260+ Infectious-related patent PDFs



 Mediated access to resources patent thumbnailnew patent Mediated access to resources
Today's user is facing an ever increasing number of cyber threats from infectious software to scam artist phishing for their passwords and other personal information. Accordingly, a technique is provided to mediate a user's access to electronic resources, which can include malware and sites that trick the user into giving their password.
Mimecast North America, Inc.


 Self assembling nucleic acid nanostructures patent thumbnailnew patent Self assembling nucleic acid nanostructures
Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of g-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of g-quadruplex stabilizing domains linked to the g-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as toll-like receptors; for inhibiting dna or rna expression; for stimulating or inhibiting an immune response; and for treating diseases such as cancer, infectious diseases, allergies and allergic diseases, and autoimmune diseases..
Exicure, Inc.


 Icos binding proteins patent thumbnailnew patent Icos binding proteins
The present invention relates to an icos binding protein or antigen binding portion thereof that is an agonist to human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Glaxosmithkline Intellectual Property Development Limited


 Bacterial phospholipase inhibitors as modulator of colonic bacterial flora patent thumbnailnew patent Bacterial phospholipase inhibitors as modulator of colonic bacterial flora
The present invention relates to the field of gastroenterology and, more particular, to the field of intestinal diseases. More specifically, it concerns uses and methods for the treatment of inflammatory bacterial diseases of the intestine.
Universitaetsklinikum Heidelberg


 Live attenuated chimeric porcine circovirus vaccine patent thumbnailnew patent Live attenuated chimeric porcine circovirus vaccine
The present invention provides a novel chimeric porcine circovirus infectious dna clone and live attenuated chimeric virus with the pcv2, preferably of subtype pcv2b, capsid gene integrated into a non-pathogenic pcv1 virus genome. In a particular embodiment, the pcv2 capids gene is of subtype pcv2b, the predominant subtype circulating in pigs worldwide.
Virginia Tech Intellectual Properties, Inc.


 Har-nds-derived stem cells,  separating same, and use thereof patent thumbnailnew patent Har-nds-derived stem cells, separating same, and use thereof
The present invention relates to hyaluronic acid-rich node and duct system (har-nds)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (ndscs), which are adult stem cells having an ability to differentiate into har-nds-derived neural cells, and hematopoietic stem cells having an ability to differentiate into blood cells. The present invention is capable of separating, from har-nds, adult stem cells ndscs and hematopoietic stem cells, which are not easy to obtain from bone marrow, peripheral blood and umbilical cord blood (cord blood), as an alternative source, and thus can be usefully used for treatment of brain diseases, neurological diseases, chronic infectious diseases, cancers, autoimmune diseases, organ regeneration treatments and various intractable diseases..
Eutilex Co., Ltd


 Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same patent thumbnailnew patent Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as peg400 but essentially free of organic solvents and non-solubilized particles.
Platform Brightworks Two, Ltd.


 Color-coded accessories indicating a medical diagnosis of a patient and enhancing patient safety patent thumbnailnew patent Color-coded accessories indicating a medical diagnosis of a patient and enhancing patient safety
The present invention provides color-coded accessories such as wristbands, bibs, and other patient wearables, color-coded pillows and pillow cases, and a universal chart wherein the color code is associated with a specific medical diagnosis. These accessories alert healthcare providers to the medical diagnosis of the patient and enhance patient safety by reducing medical errors during administration of treatments and medicines to the patients.

 Systems and methods for detecting infectious diseases patent thumbnailSystems and methods for detecting infectious diseases
Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.


 Differential diagnostic method and kit for infectious and parasitic diseases, using flow cytometry patent thumbnailDifferential diagnostic method and kit for infectious and parasitic diseases, using flow cytometry
The present invention relates to a differential diagnostic method using flow cytometry, performed by means of differential fluorescent marking of biological agents, such as cells and pathogens of interest, with fluorescent substances. The diagnostic method generally consists in performing fluorescent marking of biological agents with gradual concentrations of fluorescent substances, and in analyzing the reactivity profile of igg1 to the biological agents.
Fundacao Oswaldo Cruz


Dnazyme-nanoparticle conjugates and methods of use thereof

The present invention relates to dnazymes (also known as deoxyribozymes, dna enzymes, catalytic dna, or dz), which are conjugated to nanoparticles (np) to facilitate the detection of nucleic acids. One aspect of the invention relates to compounds comprising dnazymes conjugated to nanoparticles (dz-np), such as metallic or gold nanoparticles, and methods for their synthesis.
The University Of Notre Dame

Immunological reagents

This disclosure relates to binding agents with specificity for programmed cell death 1 (pd-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (hiv)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“p2”) on pd-1 that is linked with a previously unidentified functional activity of pd-1 that is distinct from the interaction site involved with either the pd-l1 or pd-l2 ligands.
Mabquest Sa

Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in birt-hogg-dubé syndrome, chronic erosive oral lichen planus, early stage cutaneous t-cell lymphoma, treatment of autoimmune active anterior uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), pachyonychia congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose..
Druggability Technologies Ip Holdco Limited

Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

The present application generally relates to the discovery that glycogen synthase kinase 3 (gsk-3) is an upstream signalling molecule that controls pd-1 transcription and tbet expression by immune cells and in particular t-cells. Based on this discovery, and in view of the known immunosuppressive effect of pd-1 on immunity and the promoting effect of tbet on t cell immunity, the present invention relates to the use of gsk-3 inhibitors to promote immunity, including cytotoxic t cell immunity in subjects in need thereof, especially subjects with chronic conditions wherein inhibiting pd-1 expression and/or blockade or tbet up-regulation is therapeutically desirable such as cancer and infectious conditions.

Intraocular delivery devices and methods therefor

Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall.
Ocuject, Llc

Sterile site apparatus, system, and using the same

Apparatus, system, and methods are provided for reducing infectious agents at a sterile site by preventing infectious agents from coming into contact with the sterile site. A barrier is produced for infectious agents that may come in proximity or otherwise communicate with the site.
Armour Technologies, Inc.

Chemical gel to dissolve metal and hazardous medical sharps

This dissolvent is an inorganic compound of silica gel that is stabile and lasts for decades. Pleasant gold color, no evident odor or vapor, and it will not spill, or degrade over the decades, while awaiting use.

Human monoclonal antibodies to programmed death ligand 1 (pd-l1)

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to pd-l1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E.r. Squibb & Sons, L. L. C.

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Protein kinase inhibitors

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the tec or src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated..
Pharmascience Inc.

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, y, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .

Replication-competent vesicular stomatitis viruses

This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided..
Mayo Foundation For Medical Education And Research

Time zero classification of messages

Detecting infectious messages comprises performing an individual characteristic analysis of a message to determine whether the message is suspicious, determining whether a similar message has been noted previously in the event that the message is determined to be suspicious, classifying the message according to its individual characteristics and its similarity to the noted message in the event that a similar message has been noted previously.. .
Dell Software Inc.

Improved nanoparticle type oligonucleotide structure having high efficiency and preparing same

The present invention relates to an oligonucleotide structure and a method for preparing the same and, more particularly, to an oligonucleotide structure in which a polymer compound is linked to an oligonucleotide via a covalent bond to improve in vivo stability of the oligonucleotide and cellular delivery efficiency of the oligonucleotide; and to a method for preparing the same. The oligonucleotide structure is improved into a homogenous material, thereby solving the problem in material verification due to polydispersion characteristics occurring when a hydrophilic material linked to the oligonucleotide is a synthetic polymer; the oligonucleotide structure is easy to synthesize compared with the existing process; and the size of a double-stranded oligo rna structure can be accurately adjusted through the control of the repetition number of a hydrophilic material block, and thus, the gene expression regulation function of the oligonucleotide does not deteriorate through the synthesis of the optimized oligonucleotide structure, and the oligonucleotide can be delivered into cells at even a relatively low-concentration dosage.
Bioneer Corporation

Targeted conjugates and particles and formulations thereof

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided.
Tarveda Therapeutics, Inc.

Enhanced immune response in cattle upon treatment with nitric oxide

The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease..
Bovicor Pharmatech Inc.

Methods for the treatment of infections and tumors

Pd-1 antagonists are disclosed that can be used to reduce the expression or activity of pd-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these pd-1 antagonists in conjunction with an antigen from the infectious agent or tumor.

Selective detection of haemophilus influenzae

A process for detecting haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a haemophilus influenzae nucleotide sequence and measuring the amplification product to detect haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay.

Selective detection of haemophilus influenzae

A process for detecting haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a haemophilus influenzae nucleotide sequence and measuring the amplification product to detect haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.

Dosage and administration of non-fucosylated anti-cd40 antibodies

This invention relates methods of using a non-fucosylated anti-cd40 antibody for treatment of cancer and chronic infectious diseases.. .
Seattle Genetics, Inc.

Ctla4 binders

The present invention provides molecules, such as isvds and nanobodies, that bind to ctla4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Pd1/ctla4 binders

The present invention provides multispecific molecules, e.g., comprising more than one isvd or nanobody, that bind to pd1 and ctla4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Pd1 and/or lag3 binders

The present invention provides molecules, such as isvds and nanobodies, that bind to pd1 and lag3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Antibodies to il-15

The present invention relates to antibodies binding il-15, in particular humanized antibodies. In particular, the anti-il-15 antibodies according to the invention are able to neutralize il-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or bacterial pathogens..
Calypso Biotech Sa

System for implanting, activating, and operating an implantable battery

Apparatus, systems, and methods for the treatment of bone, cartilage and other types of hard tissue. The treatments, which are suitable for extended treatment, include the treatment and prevention of pathologies through the controllable use of silver, iron, zinc, or magnesium ions.
Ortho-ion Ltd.

Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning

The invention provides isolated polynucleotide molecules that comprise a dna sequence encoding an infectious rna sequence encoding a genetically-modified north american prrs virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided..
Zoetis Services Llc

North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof

The invention provides isolated polynucleotide molecules that comprise a dna sequence encoding an infectious rna sequence encoding a genetically-modified north american prrs virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided..
Zoetis Services Llc

Recombinant rsv reporter virus

An rsv reporter strain that can be used for high-throughput drug discovery is disclosed. Also disclosed is a recombinant rsv vector that contains an rsv genome encoding the disclosed rsv reporter strain operably linked to an expression control sequence.
Georgia State University And Research Foundation, Inc.

Prrs viruses, infectious clones, mutants thereof and methods of use

This disclosure provides isolated infectious polynucleotides, such as infectious clones, having a nucleotide sequence with identity to prrs viruses such as vr-2332, lelystad, or others, and optionally further including a deletion in a region of orf1 that encodes the nsp2 polypeptide.. .
Regents Of The University Minnesota

Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual

The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the human immunodeficiency viruses (hiv) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41..
Assistance Publique Hopitaux De Paris

Live attenuated classical swine fever vaccine based in genetic manipulation of a putative fusion peptide area in the virus structural glycoprotein e2

The role of a specific e2 region, 869ckwggnwtcv878, containing a putative fusion peptide (fp) sequence was evaluated. Fps critically contribute to the interaction between proteins and the membrane system of the host cell.
The United States Of America, As Represented By The Secretary Of Agriculture

Bacteriophage and antibacterial composition comprising the same

The present invention relates to a novel bacteriophage having a specific bactericidal activity against salmonella, a composition for the prevention or treatment of infectious diseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising the bacteriophage as an active ingredient. The novel bacteriophage of the present invention has a specific bactericidal activity against salmonella choleraesuis, salmonella typhimurium, salmonella derby, salmonella infantis or salmonella newport with no influences on beneficial bacteria, as well as excellent acid- and heat-resistance and desiccation tolerance.
Cj Cheiljedang Corporation

Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity

The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity..
Universite D'aix-marseille

System and preventing transfer of infectious disease

A system and method to assist in the prevention of the transfer of infectious diseases. More particularly, a system and method that monitors and alerts caregivers to cleanse, sanitize, and/or wash their hands prior to engaging with other individuals in their care.

Methods and systems for rapid detection of microorganisms using infectious agents

Disclosed herein are methods and systems for rapid detection of microorganisms in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region.
Laboratory Corporation Of American Holdings

Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response

The present invention relates to the use of a recombinant lag-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer..
Immutep

A the treatment of glioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord

The embodiments of the present invention provide a method for the treatment of glioblastoma using wharton jelly-mesenehmal stem cells (wj-msc) derived from human umbilical cord. The mesenchymal stem cells have potential to inhibit the glioblastoma cancer cells.

Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors

And salts thereof in which r1, r2, r3, r4, x, y and n have the meanings given in the specification, are inhibitors of trk kinases and are useful in the treatment of diseases which can be treated with a trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Biotherapeutics, Inc.

Compositions comprising peroxyacid and methods for producing and using the same

The present invention provides methods for producing a non α-keto peracid that has lower toxicity and lower corrosivity. The present embodiments also provide methods and compositions for reducing microbes on a surface, methods, and compositions for preventing and reducing infectious vegetative bacteria on a substrate, and methods and compositions for treating a wound.
Chd Bioscience, Inc.

Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors

And salts thereof in which r1, r2, r3, r4, x, y and n have the meanings given in the specification, are inhibitors of trk kinases and are useful in the treatment of diseases which can be treated with a trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma, Inc.

Programmable universal cell receptors and using the same

The present invention provides programmable universal cell receptors (pucrs) comprising a catalytic antibody region, a transmembrane domain and a cytoplasmic domain. The pucrs disclosed herein may be conjugated to a specificity agent in order to program the receptor for specificity to any molecule of interest.
Sorrento Therapeutics, Inc.

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma, Inc.

Regulation of cell membrane-mediated effects

The invention features methods of inhibiting cell membrane-mediated effects of infectious microorganisms and of a variety of factors on vertebrate cells with one or more of a family of glycerol-based compounds. The cell membrane-mediated effects are those resulting in, for example, infection of the vertebrate cells by relevant infectious microorganisms and inflammatory responses to infectious microorganisms or factors..
Hennipen Life Sciences, Llc

Methods for detecting a biomarker by alternating current electrokinetics

Methods are described for detecting pathogens, infectious diseases, and physiological conditions by quantifying change of impedance over time of when a biological sample is applied onto a lab-on-a-chip. The lab-on-a-chip utilizes alternating-current electrokinetic (acek) phenomena such that molecules move or are carried in an electric field generated by the application of an electrical signal of predetermined magnitude and frequency to an electrode array of the lab-on-a-chip..
University Of Tennessee Research Foundation

Nucleic acid amplification controls

The present invention discloses positive control material for nucleic acid amplification based detection of microorganisms in biological samples. The control material comprises purified microorganism that is rendered non-infectious but is amenable to nucleic acid amplification.
Zeptometrix Corporation

Double-stranded rna conjugates and their use

Double-stranded ribonucleic acids (dsrna) of at least 45 bp, preferably of at least 50 bp, which dsrna include at least one 5′-triphosphate group and further includes at least one chemical modification at a 5′ end, at a 3′ end and/or at a non-terminal nucleotide. The invention further provides pharmaceutical compositions containing such modified dsrnas, methods for their production, and to their use in medicine, in particular for immunostimulation and treatment as well as prevention of infectious, autoimmune, degenerative, cancer and tumor diseases..
Riboxx Gmbh

Personal vaccine and making

A method for the creation of a personalized vaccine. Multiple and varied antigens in conjunction with heat shock proteins (and other protein chaperones) are generated by ionized gas lysing coupled with the separation, concentration, and purification of these chaperone protein-antigen complexes (cpac) using insulator-dielectrophoresis (i-dep)-based devices.
Q21

Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a r3 and r3a are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma, Inc.

Compounds useful as immunomodulators

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use.
Bristol-myers Squibb Company

Personal vaccine and making

A method for the creation of a personalized vaccine. Multiple and varied antigens in conjunction with heat shock proteins (and other protein chaperones) are generated by ionized gas lysing coupled with the separation, concentration, and purification of these chaperone protein-antigen complexes (cpac) using insulator-dielectrophorsis (i-dep)-based devices.
Q21

Personal vaccine and making

A method for the creation of a personalized vaccine. Multiple and varied antigens in conjunction with heat shock proteins (and other protein chaperones) are generated by ionized gas lysing coupled with the separation, concentration, and purification of these chaperone protein-antigen complexes (cpac) using insulator-dielectrophorsis (i-dep)-based devices.
Q21

Personal vaccine and making

A method for the creation of a personalized vaccine. Multiple and varied antigens in conjunction with heat shock proteins (and other protein chaperones) are generated by ionized gas lysing coupled with the separation, concentration, and purification of these chaperone protein-antigen complexes (cpac) using insulator-dielectrophorsis (i-dep)-based devices.
Q21

Assays for determining the effect of an immune cell on a cell from an infectious or neoplastic disease

An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. Also provided is an in vitro assay for determining the effect of an activated cd8+ t-cell on a sensitized melanoma cell.
The Trustees Of Columbia University In The City Of New York

Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality

The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (hsp) preparation or an α-2-macroglobulin (α2m) preparation with a non-vaccine treatment modality. In particular, an hsp preparation or an α2m preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases.
University Of Connecticut Health Center

Pharmaceutical compositions comprising danirixin for treating infectious diseases

Provided are compounds and pharmaceutically acceptable salts thereof, and combinations of compounds, their pharmaceutical compositions, their methods of preparation, and methods for their use in treating or preventing infectious disease.. .
Glaxosmithkline Intellectual Property (no. 2) Limited

Intraocular delivery devices and methods therefor

Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall.
Ocuject, Llc

Ibv strains and uses thereof

The present invention relates to novel infectious bronchitis virus strains and the uses thereof. The invention particularly relates to an inactivated or attenuated ibv, as well as to vaccine compositions comprising the same and the uses thereof to vaccinate avians.
Biomune Company

Targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution.
Tarveda Therapeutics, Inc.

Replication-competent vsv-hiv env vaccines

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of aids. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
International Aids Vaccine Initiative

Vaccination with immuno-isolated cells producing an immunomodulator

Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immuno-isolated allogeneic cells that secrete an immunomodulator such as gm-csf (granulocyte-macrophage colony stimulating factor) and an antigenic component such as autologous tumor cells or infectious agents. Also provided are kits and pharmaceutical compositions containing the vaccine compositions as well as methods of use thereof for therapeutic or preventative vaccination against tumors or infectious agents..
Maxivax Sa

Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders

The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have tlr4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Monoclonal antibodies to programmed death 1 (pd-1)

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Ono Pharmaceutical Co., Ltd.

Inhibitors of lpxc

Provided herein, inter alia, are compounds and methods for treating infectious diseases. The compounds provided herein are, inter alia, useful for the treatment of bacterial infections.
The Regents Of The University Of California

Modular antigen transportation molecules and uses thereof in animals

The present invention relates to (isolated) recombinant proteins, also referred to as improved mat (imat) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such imat molecules are useful specifically as vaccines, e.g.
Boehringer Ingelheim Vetmedica Gmbh

Cold-adapted-viral-attenuation (cava) and novel attenuated poliovirus strains

A poliovirus (pv) strain was attenuated by a novel method of cold-adapted-viral-attenuation (cava). The resulting recombinant attenuated pv, cava-pv, shows wild-type replication at 30° c., but no substantial replication at 37° c.
Crucell Holland B.v.

Vaccination with immuno-isolated cells producing an immunomodulator

Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immuno-isolated allogeneic cells that secrete an immunomodulator such as gm-c sf (granulocyte-macrophage colony stimulating factor) and an antigenic component such as autologous tumor cells or infectious agents. Also provided are kits and pharmaceutical compositions containing the vaccine compositions as well as methods of use thereof for therapeutic or preventative vaccination against tumors or infectious agents..
Maxivax Sa

1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor

Provided is compound (i) or a pharmaceutically acceptable salt thereof, which is an inhibitor of trka kinase and is useful in the treatment of diseases which can be treated with a trka kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from connective tissue growth factor aberrant signaling.. .
Array Biopharma Inc.

Treatment of inflammatory and infectious skin disorders

Disclosed herein is a composition comprising of resveratrol and/or derivatives thereof and/or functionally related compounds and benzoyl peroxide and/or derivatives thereof and/or functionally related compounds for the treatment of acne and other inflammatory or infectious skin disorders. Also disclosed are methods of treating acne and other inflammatory and infectious skin disorders using the compositions described herein..
The Regents Of The University Of California

Novel compounds

Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Treatment of skin and soft tissue infection with nitric oxide

The present invention generally relates to compositions and methods for treatment of skin and/or other soft tissues that are infected with bacteria such as staphylococcus aureus, and/or other infectious organisms. In some cases, the composition may include nitric oxide.
Transdermal Biotechnology, Inc.

Melatonin and its use in preventing postoperative complications

The invention relates to the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of l-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof, for the manufacture of a medicament for the therapeutic treatment, prophylactic treatment and/or prevention of postoperative infectious and/or non-infections complications induced by surgical interventions wherein the infectious complications may be pneumonia, wound infection (wound dehiscence), intra-abdominal abscess, and urinary tract infections (uti) or wherein the non-infectious complication may be anastomotic leak, a pharmaceutical formulation comprising melatonin and at least one compound selected from the group consisting of l-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof and a method for the therapeutic and/or prophylactic treatment of postoperative infectious and/or non-infectious complications induced by surgical interventions.. .
Nutri-fit Gmbh & Co. Kg

Female urinary barrier system

A female urinary barrier system product that includes an exterior vaginal attachment pad for providing a female-user with means to prevent the spread of infectious diseases into their vaginal opening and urinary tract. The product provides a female-user a hand depressible attachment pad useful for enclosing/covering the vagina prior to a bowel movement or just prior to wiping.

Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples

The invention is directed to compositions and methods for rapidly detecting, amplifying, and quantitating one or more pathogen-specific nucleic acids in a biological sample, and in particular, samples obtained from patients with sepsis. The invention also provides diagnostic kits containing specific amplification primers, and labeled detection probes that specifically bind to the amplification products obtained therefrom.
Longhorn Vaccines And Diagnostics, Llc

Methods for diagnosing infectious diseases using adsorption media

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen.
Exthera Medical Corporation

Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease

The invention relates to the field of cell therapy, particularly nk cell mediated therapy. The present invention relates to a method of producing an ex vivo population of cells, preferably nk cells, from at least two umbilical cord blood units (ucb units), or fraction thereof containing said cells, by pooling said at least two ucb units to produce said population of cells.
Institut National De La Sante Et De Recherche Medicale (inserm)

A chimeric peptide that interacts with cell membrane gangliosides

The invention relates to a chimeric peptide displaying the ganglioside-binding properties of both α-synuclein and β-amyloid peptide. Such peptide is useful in preventing or treating any condition which involves gangliosides as cell surface receptor sites, including neurodegenerative disorders, infectious diseases, or tumors..
Universite D'aix-marseille

Antimicrobial peptides

A novel antimicrobial peptide includes at least eight successive amino acids, the peptide exhibiting a sequence having the following formula: ter1-x1—b1—x2—b2—x3—z1—z2—x4-ter2. The peptide can moreover also have modified termini.
Robert Bosch Gesellschaft FÜr Medizinische Forschung Mbh

Suprametallogels and uses thereof

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology

Composition for treating hbv infection

The present invention provides a composition comprising hepatitis b virus (hbv) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such hbv component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors.
Transgene S.a.

Toll-like receptor 2 agonists and vaccines and uses thereof

The present invention relates to toll-like receptor 2 (tlr2) agonists, in particular, to tlr2-activating lipoproteins, and more particularly to tlr2-activating lipopeptides derived from the bacteria bordetella pertussis. The invention further extends to the use of said tlr2-activating lipoproteins as a therapeutic or as part of a vaccine composition in the treatment and prevention of infectious diseases, cancer or allergic diseases..
The Provost, Fellows, Foundation Scholars & The Other Members Of Board, Of The College Of The Holy

Multivalent vlp conjugates

The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (vlp), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents.
Inventprise, Llc

Methionine aminopeptidase inhibitors for treating infectious diseases

The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof..
Texas Southern University

Methionine aminopeptidase inhibitors for treating infectious diseases

The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof..
The Board Of Regents Of The University Of Texas System

Methionine aminopeptidase inhibitors for treating infectious diseases

The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof..
The Board Of Regents Of The University Of Texas System

Therapeutic agent for keratoconjunctive disorders

The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a rarγ agonist as an active ingredient is provided.
Yamaguchi University

Immunoassay test device with two fluid flow paths for detection and differentiation of two or more analytes

A device for determining presence or absence of infection due to an infectious agent is described. The device comprises a sample receiving zone configured to receive a liquid sample from a subject suspected of having an infection due to an infectious agent, the sample receiving zone positioned to distribute the sample along a first fluid flow path to a first label zone and along a second fluid flow path to a second label zone.
Quidel Corporation

Devices, detecting viable infectious agents in a fluid sample

Various devices, systems and methods for detecting a susceptibility of an infectious agent to an anti-infective are described herein. A method comprises introducing a fluid sample to a first surface and a second surface; exposing the first surface to a first solution; exposing the second surface to a second solution, wherein the second surface comprises an anti-infective; sampling the first solution after exposing the first solution to the first surface; sampling the second solution after exposing the second solution to the second surface; monitoring a first electrical characteristic of a first sensor exposed to the first solution sampled; monitoring a second electrical characteristic of a second sensor exposed to the second solution sampled; and comparing the first electrical characteristic and the second electrical characteristic to assess the susceptibility of the infectious agent to the anti-infective..
Esense, Llc

Devices, detecting viable infectious agents in a fluid sample

Various devices, systems and methods for detecting a susceptibility of an infectious agent to an anti-infective are described herein. A method comprises introducing a fluid sample to a first surface and a second surface; exposing the first surface to a first solution; exposing the second surface to a second solution, wherein the second surface comprises an anti-infective; sampling the first solution after exposing the first solution to the first surface; sampling the second solution after exposing the second solution to the second surface; monitoring a first electrical characteristic of a first sensor exposed to the first solution sampled; monitoring a second electrical characteristic of a second sensor exposed to the second solution sampled; and comparing the first electrical characteristic and the second electrical characteristic to assess the susceptibility of the infectious agent to the anti-infective..
Esense, Llc

Generation of infectious influenza viruses from virus-like particles

Compositions and methods to prepare influenza virus-like particles (vlps) are provided.. .

Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon

Wherein r1 is hydrogen, methyl or —(ch2)2or3, r2 is methyl or —(ch2)2or4, or r1 and r2, together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents; r3 and r4 are each independently hydrogen or methyl; and n is an integer having a value of 5 or 6, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment or prevention of various disorders, for example the treatment or prevention of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Integrated health data capture and analysis system

The present invention provides an integrated health care surveillance and monitoring system that provides real-time sampling, modeling, analysis, and recommended interventions. The system can be used to monitor infectious and chronic diseases.
Theranos, Inc.

Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the nrp-1/obr signaling pathway..
Universite De Bourgogne

Method for treating infectious diseases using emissive energy

The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser or other high-energy source of emissive radiation.
Marv Enterprises, Llc

Infectious laryngotracheitis virus (iltv) vaccine using recombinant newcastle disease virus vector

In this study, for the first time, protective efficacy of gd against iltv challenge was evaluated. Immunization with recombinant newcastle disease virus expressing iltv gd induced a higher level of neutralizing antibodies and offered complete protection to chickens against lethal iltv challenge.
University Of Maryland

Methods of measuring antigen-specific t cells

Provided herein are methods and kits for assaying antigen-specific t cell responses, such as rare autoantigen-specific t cell responses, by measuring a level of ip-10 in a sample from a subject having or suspected of having an autoimmune disease, an allergy, an infectious disease or condition, or an adverse immune condition caused by administration of an isolated, recombinant or synthetic protein or peptide. Also provided herein are methods and kits for assaying a t cell response to an antigen peptide, such as an islet autoantigen peptide, such as measuring a t cell response to at least one antigen peptide, such as an islet autoantigen peptide, in a sample from a subject, such as one having or suspected of having type 1 diabetes (tid), celiac disease or both..
Immusant, Inc.

Methods of detecting signatures of disease or conditions in bodily fluids

Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided.
President And Fellows Of Harvard College

Bacterial phospholipase inhibitors as modulator of colonic bacterial flora

The present invention relates to the field of gastroenterology and, more particular, to the field of intestinal diseases. More specifically, it concerns uses and methods for the treatment of inflammatory bacterial diseases of the intestine.
Universitaetsklinikum Heidelberg

Compositions having means for targeting at least one antigen to dendritic cells

A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a cpg oligodeoxynucleotide and/or a cpg-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases..
Universite Paris Descartes

Novel bacteriophage and composition comprising same

The present invention relates to a novel bacteriophage Φcj25 (kccm11463p) and a composition comprising the same as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic escherichia coli (apec) of birds by using the bacteriophage Φcj25 (kccm11463p) or the composition..
Cj Cheiljedang Corporation

Chimeric viruses presenting non-native surface proteins and uses thereof

The present invention provides chimeric negative-stand rna viruses that allow a subject, e.g., an avian, to be immunized against two infectious agents by using a single chimeric virus of the invention. In particular, the present invention provides chimeric influenza viruses engineered to express and incorporate into their virions a fusion protein comprising an ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an influenza virus protein.
Icahn School Of Medicine At Mount Sinai

Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin m (igm)

Compositions and methods of the present invention prevent, inhibit or reduce the toxic effects of proteins and toxins secreted from microbes. A method for neutralizing microbial protein products in a subject comprises administering a composition to the subject, said composition comprising plasma-derived igm and optionally one or more excipients in a pharmaceutical carrier, wherein the composition is administered in an amount effective to neutralize the microbial protein products..
Grifols Worldwide Operations Limited

Multi-functional mucosal vaccine platform

An immunogenic fusion protein for use as a mucosal vaccine is provided, which includes: i) one or more fcyri-binding domains; ii) one or more antigens from one or more infectious disease organisms; and iii) one or more fcrn-binding domains.. .
University Of Washington

Nkt cell ligands and methods of use

Alpha-glycosylceramide compounds capable of activating nkt cells and compositions thereof are disclosed. Methods for activating nkt cells, methods of stimulating an immune response in a subject, and methods of treating cancer, infectious diseases, autoimmune diseases and disorders, or allergy diseases or disorders with the compounds and compositions are also disclosed..
Brigham Young Unversity

Novel macrocyclic compounds

The present invention relates to novel macrocyclic compounds of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Methionine analogs and methods of using same

Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties.
Bioxiness Pharmaceuticals, Inc.



Infectious topics:
  • Infectious
  • Infectious Disease
  • Infectious Diseases
  • Autoimmune
  • Autoimmune Disease
  • Immune Disease
  • Modulation
  • Nucleotide
  • Killer Cells
  • Natural Killer Cell
  • Stem Cells
  • Amplification
  • Dna Sequence
  • Single Nucleotide Polymorphism
  • Nucleic Acid


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Infectious for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Infectious with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.7346

    file did exist - 12927

    2 - 1 - 254